CA19-9 is a significant prognostic marker of patients with stage III gastric cancer

被引:19
|
作者
Kambara, Yuichi [1 ]
Miyake, Hideo [1 ]
Nagai, Hidemasa [1 ]
Yoshioka, Yuichiro [1 ]
Shibata, Koji [1 ]
Asai, Soichiro [1 ]
Yuasa, Norihiro [1 ]
机构
[1] Japanese Red Cross Nagoya First Hosp, Dept Gastrointestinal Surg, Nakamura Ku, 3-35 Michishita Cho, Nagoya, Aichi 4538511, Japan
来源
EJSO | 2020年 / 46卷 / 10期
关键词
CA19-9; Prognosis; Gastric cancer; Value dependency; Risk stratification; CARBOHYDRATE ANTIGEN 19-9; SERUM-LEVELS; CA-19-9; LEWIS; CEA; SURVIVAL; SECRETOR;
D O I
10.1016/j.ejso.2020.05.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Due to prognostic heterogeneity within a stage of gastric cancer (GC), identification of patients with a high risk for recurrence after resection is important. We aimed to identify the prognostic significance of preoperative serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels in patients with Stage I, II, and III GC who underwent R0 gastrectomy. Methods: A total of 794 patients were included in this study after excluding 72 patients with CA19-9 <1.0 U/mL. Receiver operating characteristic curves were drawn to assess the optimal cut-off values of CEA and CA19-9 for disease recurrence. Results: The optimal cut-off values of CEA and CA19-9 levels were 2.9 ng/mL and 46.3 U/mL, respectively. Multivariate analysis for relapse-free survival (RFS) showed that stage of GC, CA19-9 levels, postoperative adjuvant chemotherapy, and venous invasion were significant independent factors. The RFS and overall survival (OS) of patients with CA19-9 >= 46.3 U/mL were significantly lower than those with CA19-9 < 46.3 U/mL in Stage III GC. However, the RFS of GC patients with CA19-9 >= 463 U/mL tended to be better than those with CA19-9 levels between 46.3 and 463 U/mL. Conclusions: The RFS and OS of patients with CA19-9 >= 46.3 U/mL were significantly lower than those with CA19-9 < 46.3 U/mL in Stage III GC. However, there was no value dependency of extremely elevated CA19-9 on RFS. Further risk stratification can be obtained by measuring preoperative serum CA19-9 in stage III GC. (C) 2020 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
引用
收藏
页码:1918 / 1924
页数:7
相关论文
共 50 条
  • [21] IMMUNOHISTOCHEMICAL STUDY OF CA19-9 IN GASTRIC-CANCER
    AFDHAL, AN
    OCONNOR, H
    CULLEN, A
    DIXON, MF
    AXON, ATR
    ODONOGHUE, DP
    JOURNAL OF PATHOLOGY, 1986, 149 (03): : A247 - A248
  • [22] The Advancement Stage of Gastric Cancer and the Levels of CEA and Ca19-9 in Serum and Peritoneal Lavage
    Bak, Michal
    Wojciech, Magdalena
    Pielech, Adrianna
    Holka, Sylwia
    Zawadzki, Marek
    Murawa, Dawid
    BIOMEDICINES, 2024, 12 (11)
  • [23] Significance of CEA and CA19-9 Combination as a Prognostic Indicator and for Recurrence Monitoring in Patients with Stage II Colorectal Cancer
    Shibutani, Masatsune
    Maeda, Kiyoshi
    Nagahara, Hisashi
    Ohtani, Hiroshi
    Sakurai, Katsunobu
    Toyokawa, Takahiro
    Kubo, Naoshi
    Tanaka, Hiroaki
    Muguruma, Kazuya
    Ohira, Masaichi
    Hirakawa, Kosei
    ANTICANCER RESEARCH, 2014, 34 (07) : 3753 - 3758
  • [24] Prognostic values of CEA, CA19-9, and CA72-4 in patients with stages I-III colorectal cancer
    Wu, Tiantong
    Mo, Yali
    Wu, Chengtang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2020, 13 (07): : 1608 - 1614
  • [25] Serum CA19-9 in patients with endometrial cancer
    Hashiguchi, Yasunori
    Kasai, Mari
    Fukuda, Takeshi
    Ichimura, Tomoyuki
    Yasui, Tomoyo
    Sumi, Toshiyuki
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer
    Asaoka, Tadafumi
    Miyamoto, Atsushi
    Maeda, Sakae
    Tsujie, Masanori
    Hama, Naoki
    Yamamoto, Kazuyoshi
    Miyake, Masakazu
    Haraguchi, Naotsugu
    Nishikawa, Kazuhiro
    Hirao, Motohiro
    Ikeda, Masataka
    Sekimoto, Mitsugu
    Nakamori, Shoji
    PANCREATOLOGY, 2016, 16 (03) : 434 - 440
  • [27] Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer
    Lakemeyer, Leilani
    Sander, Silvia
    Wittau, Mathias
    Henne-Bruns, Doris
    Kornmann, Marko
    Lemke, Johannes
    DISEASES, 2021, 9 (01)
  • [28] Prognostic and predictive value of CA19-9 in metastatic colorectal cancer
    Narita, Yukiya
    Taniguchi, Hiroya
    Komori, Azusa
    Nitta, Sohhei
    Yamaguchi, Kazuhisa
    Kondoh, Chihiro
    Kadowaki, Shigenori
    Takahari, Daisuke
    Ura, Takashi
    Andoh, Masashi
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [29] The Value of CA125 and CA19-9 in the Diagnosis of Stage III and IV Endometriosis
    Zhang, Wenwen
    Tang, Huimin
    Jia, Qiucheng
    Chen, Jiming
    Zhu, Genhai
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2024, 51 (02):
  • [30] THE CLINICAL EFFICACY OF CA-72-4 AS A SERUM MARKER FOR GASTRIC-CANCER IN COMPARISON WITH CA19-9 AND CEA
    KODAMA, I
    KOUFUJI, K
    KAWABATA, S
    TETSU, S
    TSUJI, Y
    TAKEDA, J
    KAKEGAWA, T
    INTERNATIONAL SURGERY, 1995, 80 (01) : 45 - 48